Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Comparative efficacy of pharmacological interventions for contrast-induced nephropathy prevention after coronary angiography: a network meta-analysis from randomized trials

Comparative efficacy of pharmacological interventions for contrast-induced nephropathy prevention... Background Contrast-induced nephropathy (CIN) is the major complication related to contrast media administration in patients after coronary angiography (CAG). However, inconsistent results have been published in the literature regarding the effects of pharmacological drugs on CIN prevention. We conducted a network meta-analysis to evaluate the relative efficacy of pharmacological interventions for the prevention of CIN. Methods We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from inception to July 2017. We included any randomized controlled trials of eleven pharmacological interventions that reported the prevention of CIN. Results We identified 3850 records through database searches, of which 107 studies comprising 21,450 participants were finally identified. Compared with intravenous saline, intravenous saline plus pharmacological drugs including statin [rela - tive risk (RR) 0.57; 95% credibility interval (CrI) 0.39 to 0.83], N-acetylcysteine (NAC) (RR 0.84; 95% CrI, 0.71 to 0.98), vitamin and its analogues (RR 0.66; 95% CrI 0.45 to 0.97), brain natriuretic peptide (BNP) and its analogues (RR 0.46; 95% CrI 0.30 to 0.70), prostaglandin analogues (RR 0.37; 95% CrI 0.18 to 0.76), NAC plus sodium bicarbonate (SB) (RR 0.60; 95% CrI 0.39 to 0.90), and statin plus NAC (RR 0.39; 95% CrI 0.21 to 0.70), have helped http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Urology and Nephrology Springer Journals

Comparative efficacy of pharmacological interventions for contrast-induced nephropathy prevention after coronary angiography: a network meta-analysis from randomized trials

Download PDF
11 pages

Loading next page...
 
/lp/springer_journal/comparative-efficacy-of-pharmacological-interventions-for-contrast-XepYj0dmQl
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media B.V., part of Springer Nature
Subject
Medicine & Public Health; Nephrology; Urology
ISSN
0301-1623
eISSN
1573-2584
DOI
10.1007/s11255-018-1814-0
pmid
29404930
Publisher site
See Article on Publisher Site

Abstract

Background Contrast-induced nephropathy (CIN) is the major complication related to contrast media administration in patients after coronary angiography (CAG). However, inconsistent results have been published in the literature regarding the effects of pharmacological drugs on CIN prevention. We conducted a network meta-analysis to evaluate the relative efficacy of pharmacological interventions for the prevention of CIN. Methods We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from inception to July 2017. We included any randomized controlled trials of eleven pharmacological interventions that reported the prevention of CIN. Results We identified 3850 records through database searches, of which 107 studies comprising 21,450 participants were finally identified. Compared with intravenous saline, intravenous saline plus pharmacological drugs including statin [rela - tive risk (RR) 0.57; 95% credibility interval (CrI) 0.39 to 0.83], N-acetylcysteine (NAC) (RR 0.84; 95% CrI, 0.71 to 0.98), vitamin and its analogues (RR 0.66; 95% CrI 0.45 to 0.97), brain natriuretic peptide (BNP) and its analogues (RR 0.46; 95% CrI 0.30 to 0.70), prostaglandin analogues (RR 0.37; 95% CrI 0.18 to 0.76), NAC plus sodium bicarbonate (SB) (RR 0.60; 95% CrI 0.39 to 0.90), and statin plus NAC (RR 0.39; 95% CrI 0.21 to 0.70), have helped

Journal

International Urology and Nephrology – Springer Journals

Published: Feb 5, 2018

References

  • Contrast-induced nephropathy remains a serious complication of PCI
    Mehran, R
  • Outcomes of contrast-induced nephropathy: experience in patients undergoing cardiovascular intervention
    McCullough, P
  • Contrast-induced nephropathy following angiography and cardiac interventions
    Rear, R; Bell, RM; Hausenloy, DJ
  • Contrast-induced acute kidney injury: how should at-risk patients be identified and managed?
    Laville, M; Juillard, L
  • Contrast-induced acute kidney injury
    McCullough, PA
  • Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial
    Weisbord, SD; Gallagher, M; Kaufman, J; Cass, A; Parikh, CR; Chertow, GM; Shunk, KA; McCullough, PA; Fine, MJ; Mor, MK; Lew, RA; Huang, GD; Conner, TA; Brophy, MT; Lee, J; Soliva, S; Palevsky, PM
  • Contrast-induced nephropathy: definition, epidemiology, and patients at risk
    Mehran, R; Nikolsky, E
  • Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy
    Narula, A; Mehran, R; Weisz, G; Dangas, GD; Yu, J; Genereux, P; Nikolsky, E; Brener, SJ; Witzenbichler, B; Guagliumi, G; Clark, AE; Fahy, M; Xu, K; Brodie, BR; Stone, GW
  • Impact of metabolic syndrome on development of contrast-induced nephropathy after elective percutaneous coronary intervention among nondiabetic patients
    Ozcan, OU; Er, HA; Gulec, S; Ustun, EE; Gerede, DM; Goksuluk, H; KayaCetinErol, CT
  • Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy
    Heyman, SN; Rosen, S; Rosenberger, C
  • Contrast-induced nephropathy: pathogenesis and new therapeutic options for prevention
    Ortega, LM; Harmouch, I; Nayer, A
  • Pathophysiology of contrast-induced nephropathy
    Wong, PC; Li, Z; Guo, J; Zhang, A
  • Contrast-induced nephropathy in patients undergoing elective and urgent procedures
    Mautone, A; Brown, JR
  • Prophylaxis of contrast-induced nephrotoxicity
    Ludwig, U; Keller, F
  • How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations
    Solomon, R; Deray, G
  • Contrast induced nephropathy: updated ESUR contrast media safety committee guidelines
    Stacul, F; Molen, AJ; Reimer, P; Webb, JAW; Thomsen, HS; Morcos, SK; Almén, T; Aspelin, P; Bellin, M-F; Clement, O
  • KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury
    Palevsky, PM; Liu, KD; Brophy, PD; Chawla, LS; Parikh, CR; Thakar, CV; Tolwani, AJ; Waikar, SS; Weisbord, SD
  • Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group
    Bellomo, R; Ronco, C; Kellum, JA; Mehta, RL; Palevsky, P
  • Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury
    Mehta, RL; Kellum, JA; Shah, SV; Molitoris, BA; Ronco, C; Warnock, DG; Levin, A
  • A new protocol using sodium bicarbonate for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography
    Motohiro, M; Kamihata, H; Tsujimoto, S; Seno, T; Manabe, K; Isono, T; Sutani, Y; Yuasa, F; Iwasaka, T
  • Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty—contrast-induced nephropathy] trial
    Patti, G; Ricottini, E; Nusca, A; Colonna, G; Pasceri, V; D’Ambrosio, A; Montinaro, A; Sciascio, G
  • Short-term high-dose vitamin E to prevent contrast medium-induced acute kidney injury in patients with chronic kidney disease undergoing elective coronary angiography: a randomized placebo-controlled trial
    Rezaei, Y; Khademvatani, K; Rahimi, B; Khoshfetrat, M; Arjmand, N; Seyyed-Mohammadzad, MH
  • N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial
    Jo, SH; Koo, BK; Park, JS; Kang, HJ; Kim, YJ; Kim, HL; Chae, IH; Choi, DJ; Sohn, DW; Oh, BH; Park, YB; Choi, YS; Kim, HS
  • Effectiveness of N-acetylcysteine for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis of randomized controlled trials
    Xu, R; Tao, A; Bai, Y; Deng, Y; Chen, G
  • Effectiveness of prevention strategies for contrast-induced nephropathy: a systematic review and meta-analysis
    Subramaniam, RM; Suarez-Cuervo, C; Wilson, RF; Turban, S; Zhang, A; Sherrod, C; Aboagye, J; Eng, J; Choi, MJ; Hutfless, S; Bass, EB
  • Role of N-acetylcysteine to prevent contrast-Induced nephropathy: a meta-analysis
    Loomba, RSSP; Aggarwal, S; Arora, RR
  • Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis
    Brown, JR; Block, CA; Malenka, DJ; O’Connor, GT; Schoolwerth, AC; Thompson, CA
  • The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations
    Hutton, B; Salanti, G; Caldwell, DM; Chaimani, A; Schmid, CH; Cameron, C; Ioannidis, JP; Straus, S; Thorlund, K; Jansen, JP; Mulrow, C; Catala-Lopez, F; Gotzsche, PC; Dickersin, K; Boutron, I; Altman, DG; Moher, D
  • Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool
    Corbett, MS; Higgins, JP; Woolacott, NF
  • Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool
    Salanti, G
  • Bayesian approaches to random-effects meta-analysis: a comparative study
    Smith, TC; Spiegelhalter, DJ; Thomas, A
  • Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
    Salanti, G; Ades, AE; Ioannidis, JP
  • Graphical tools for network meta-analysis in STATA
    Chaimani, A; Higgins, JP; Mavridis, D; Spyridonos, P; Salanti, G
  • Simulation evaluation of statistical properties of methods for indirect and mixed treatment comparisons
    Song, F; Clark, A; Bachmann, MO; Maas, J
  • Checking consistency in mixed treatment comparison meta-analysis
    Dias, S; Welton, NJ; Caldwellb, DM; Ades, AE
  • Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide
    Morikawa, S; Sone, T; Tsuboi, H; Mukawa, H; Morishima, I; Uesugi, M; Morita, Y; Numaguchi, Y; Okumura, K; Murohara, T
  • Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention
    Spargias, K; Adreanides, E; Demerouti, E; Gkouziouta, A; Manginas, A; Pavlides, G; Voudris, V; Cokkinos, DV
  • Effect of renin-angiotensin system inhibitors on long-term survival in patients treated with beta blockers and antiplatelet agents after acute myocardial infarction (from the MONICA/KORA Myocardial Infarction Registry)
    Amann, U; Kirchberger, I; Heier, M; Zirngibl, A; Scheidt, W; Kuch, B; Peters, A; Meisinger, C
  • Contrast-induced nephropathy and long-term adverse events: cause and effect?
    Solomon, RJ; Mehran, R; Natarajan, MK; Doucet, S; Katholi, RE; Staniloae, CS; Sharma, SK; Labinaz, M; Gelormini, JL; Barrett, BJ
  • Randomized trial of bicarbonate or saline study for the prevention of contrast-induced nephropathy in patients with CKD
    Solomon, R; Gordon, P; Manoukian, SV; Abbott, JD; Kereiakes, DJ; Jeremias, A; Kim, M; Dauerman, HL; Investigators, BT
  • Effects of hydration in contrast-induced acute kidney injury after primary angioplasty: a randomized, controlled trial
    Maioli, M; Toso, A; Leoncini, M; Micheletti, C; Bellandi, F
  • Effect of rhBNP on renal function in STEMI-HF patients with mild renal insufficiency undergoing primary PCI
    Xing, K; Fu, X; Wang, Y; Li, W; Gu, X; Hao, G; Miao, Q; Li, S; Jiang, Y; Fan, W; Geng, W